Highlights of Ending Age-Related Diseases 2020
Key points from 20 presentations from world-leading researchers
Join the club for FREE to access the whole archive and other member benefits.
Co-Chief Executive Officer and Co-founder of Cyclarity Therapeutics (former Underdog Pharmaceuticals)
Dr. O’Connor was awarded his Master’s degree in neuroscience from Northwestern Medical in 1999 and his PhD in Biochemistry from Baylor College of Medicine in 2005. His postdoctoral research includes work at UC Berkeley on muscle stem cells and aging. He is the author of 10 published manuscripts and lead inventor on the cyclodextrin patents. He is the outgoing VP of Research at SENS Research Foundation.
Visit website: https://underdogpharma.com/team/
See also: Cyclarity Therapeutics - Company developing simple and direct interventions targeting toxic forms of cholesterol for age-related diseases
Details last updated 11-Mar-2020
Matthew O'Connor discusses the progress of developing a new biotechnology platform
Matthew O'Connor discusses the development of new drugs based on cyclodextrins
Company developing simple and direct interventions targeting toxic forms of cholesterol for age-related diseases
Dr. Matthew O'Connor provides updates on a drug targeting the removal of 7-keto cholesterol
Research company that helps people join the Longevity Biotechnology industry through education and more
Feature length documentary about longevity and radical life extension with due to be released in 2023
18-Sep-2022 to 20-Sep-2022
Event gathering Global Longevity and Rejuvenation community in Dublin with many longevity movement superstars as speakers
13-Jun-2024 to 16-Jun-2024
Event gathering Global Longevity and Rejuvenation community in Dublin by LEV Foundation (Dublin, Ireland)
Matthew O’Connor delivers a keynote on the translation of 7-Ketocholesterol clearance
Key points from 20 presentations from world-leading researchers
A great summary of 25 speakers who are in various stages of platform building, drug discovery and clinical trials
The company is developing a drug called UDP-003 to treat the disease
Safe and potential compound shows disease-modifying effect by removing toxic cholesterol from blood